



## WI AMEROM INTERNATIONAL BREAST CANCER SYMPOSIUM

ORGANIZED BY THE ASOCIACION DE MEDICOS EX RESIDENTES DE ONCOLOGIA MEDICA PERU

> Organizing Committee: Board of Directors AMEROM 2023 - 2025

> > Coordinator:

Ashley Efrain Alarcon Rozas MD. MBA.

## **PROGRAM**

## Chairman:

Ashley Efrain Alarcon Rozas MD. MBA.

Past President AMEROM. Coordinator of the International Symposium on Breast Cancer. Oncology Service Physician, Hospital Nacional Guillermo Almenara. Head of the Clinical Research and Oncology Service, Santa Beatriz Clinic. Universidad Peruana Cavetano Heredia – Lima, Peru

09:00-09:25 Hypofractionated Radiotherapy in patients with Breast Cancer (HRBC) when it is really necessary? Could we avoid RT in some patients according to the type of cancer, age or any other factor?

Budhi Singh Yadav MD.

Professor, Department of Radiation Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.

09:25-09:50 Quality, cost and survival: can real-world data help to solve the equation?

Marina Andrea Borges, MSc

Oncology Evidence Network, IQVIA, Lisbon, Portugal.

09:50-10:15 The AI will replace the interpretation of Her2 by pathologists in BC, Pros and Against


Daniel Enrique Castro Vela MD.

Medical Pathologist. Department of Pathological Anatomy. Hospital Nacional Guillermo Almenara - EsSalud - Lima, Peru.

WWW.BIT.LY/VIIBREASTCANCER

AstraZeneca 2







10:15-10:45 Panel for Discussion

Chairman Marina Andrea Borges, MSc

Cochair: Ashley Efrain Alarcon Rozas MD. MBA.

10:45-11:30 SYMPOSIUM ASTRAZENECA: Past and Present of

**HER2 mBC treatment** 

Carlos Henrique dos Anjos MD.

Medical Oncologist. Sirio-Libanes Hospital, Sao Paulo, Brasil

11:30-11:55 For CDK4/6 inhibitors what are the differences and what are the coincidences?

Ruth M. O'Regan MD.

Chair of Medicine and Charles A. Dewey Professor at the University of Rochester. Rochester, New York, USA.

11:55-12:20 What we learn in the last decade about genetic platforms like Foundation one, Caris, etc. related to actionable genes, Does they work in every case?

Edwin Mateo Quispe Bellido MD, MSc

Medical Oncologist, Clinical Investigator. Experimental Therapeutics Unit, NEXT Oncology Madrid, Hospital Universitario Quirónsalud Madrid. España.

12:20-12:45 Breast Cancer HER2 low. Definitions and treatment Carlos Arturo Castañeda Altamirano MD.

Medical Oncologist - Instituto Nacional de Enfermedades Neoplásicas. Lima, Peru.

12:45-13:10 Panel for Discussion
Chairman: Ruth M. O'Regan MD.

Cochair: Ashley Efrain Alarcon Rozas MD. MBA.

13:10-13:40 SYMPOSIUM ROCHE: Beyond the efficacy and safety of the dual blockade in the treatment of the HER2 positive breast cancer.

Fernando Petracci MD.

 $\label{lem:medicalOncologist-breast cancer specialist. Instituto Alexander Fleming. \ Buenos \ Aires, Argentina.$ 

13:40-13:50 **Questions** 

13:50-14:15 Can liquid biopsies (CTCs, ctDNA) be used as prognostic biomarkers in early breast cancer?

Carlos Barron, PhD

 $Molecular\,biologist.\,Barron\,Biomedical.\,Berlin, Germany.$ 


14:15-14:40 Cardiotoxicity in Oncology

German Victor Valenzuela Rodriguez MD.

Cardiologist. Clinica AUNA. Lima, Peru.

COLABORADORES:
AstraZeneca







14:40-15:05 Challenges for cancer prevention in Peru

Diego Rolando Venegas Ojeda MD.

Medica Oncologist. Universidad Peruana Cayetano Heredia. Lima, Peru.

15:05-15:35 Panel for Discussion

**Chairman:** Carlos Barron

Cochair: Ashley Efrain Alarcon Rozas MD. MBA.

15:35-16:05 SYMPOSIUM ROCHE: The relevance of the complete pathological response as a prognostic factor and therapeutic decisor for the adjuvant treatment in HER2 positive early breast cancer.

Fernando Petracci MD.

Medical Oncologist - breast cancer specialist. Instituto Alexander Fleming. Buenos Aires, Argentina.

16:05-16:15 **Questions** 

16:15-16:40 What is the ideal time for women with eBC who desire to become pregnant in HR positive, Her2 Positive and TNBC? Osbert Luis Mejia Palomino MD.

Medical Oncologist. Medical Oncology Service - Hospital Nacional Adolfo Guevara Velasco Essalud. Universidad Andina. Cusco, Peru.

## 16:40-17:05 New Challenge for Al in Oncology Yull Arriaga Medrano MD.

Oncologist - hematologist. Research doctor at the Center for Research, Evaluation and Artificial Intelligence (CARE) within IBM Watson Health (WH). Associate clinical professor of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas, USA.

17:05-17:30 **GEP that help who will respond in neoadjuvant therapy** Ashley Efrain Alarcon Rozas MD. MBA.

Past President AMEROM. Coordinator of the International Symposium on Breast Cancer. Oncology Service Physician, Hospital Nacional Guillermo Almenara. Head of the Clinical Research and Oncology Service, Santa Beatriz Clinic. Universidad Peruana Cayetano Heredia – Lima, Peru.

17:30-18:00 Panel for Discussion

Chairman: Yull Arriaga Medrano MD.

Cochair: Ashley Efrain Alarcon Rozas MD. MBA.

18:00 Closing



